CAPR: Capricor Therapeutics, Inc.
Performance
CAPR +66.10%
Watchlist
Select an item
Summary
CAPR at a glance
CAPR returned +66.10% over the past year and +21.37% a year over five years. Its worst drop in that year was -89.11%, smaller than 0% of stocks on Redstone, and its Sharpe ratio of 0.93 beats 72% of stocks on Redstone. It pays no dividends.
Current Drawdown
-72.13%
Rolling Volatility
112.51%
Actions
Metrics
Risk Indicators
Alpha352.80%
Beta1.39x
Sharpe0.93
Sortino3.88
Omega1.61
Calmar0.74
Martin7.99
Profile
About CAPR
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs.
- Sector
- Health Care
- Industry
- Pharmaceutical Preparations
- Market cap
- $573M
- Listed
- Jun 2002
- Employees
- 231
- Headquarters
- San Diego, CA
- Website
- capricor.com
Comparisons